DexCom, Inc. (DXCM) Stock Forecast
DXCM analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.66 / 5 from 29 analysts
- Price target
- $96.46 average of analyst targets
- Upside to target
- +12.1% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $0.66
- 52-week range
- $54.84 – $92.34
DXCM analyst ratings
29 analystsNumber of analysts at each rating.
DXCM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DXCM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.67 | $0.63 | $0.72 | $0.61 | +10.5% | 23 |
| Current fiscal year (2026) | $2.66 | $2.45 | $2.75 | $2.09 | +27.4% | 26 |
| Next fiscal year (2027) | $3.12 | $2.83 | $3.38 | $2.66 | +17.3% | 26 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DXCM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.33B | $1.31B | $1.34B | +9.8% | 25 |
| Current fiscal year (2026) | $5.23B | $5.20B | $5.26B | +12.2% | 27 |
| Next fiscal year (2027) | $5.79B | $5.64B | $5.90B | +10.8% | 27 |
DXCM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DXCM revenue: reported and forecast
DXCM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.67 | $0.67 | $0.67 | $0.67 | $0.67 | +0.2% | 1 up · 1 down |
| Current fiscal year (2026) | $2.59 | $2.66 | $2.66 | $2.66 | $2.66 | +2.9% | 1 up · 1 down |
| Next fiscal year (2027) | $3.08 | $3.12 | $3.12 | $3.13 | $3.12 | +1.5% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DXCM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DXCM beat in 10 of 12.
What analysts expect from DXCM
29 analysts cover DexCom; their consensus rating is strong buy (4.66 on a 1–5 scale, where 5 is a strong buy). The average price target is $96.46, 12.1% above the latest close of $86.04. Analysts expect earnings of $2.66 per share for 2026, +27.4% from a year earlier. For 2027 the average estimate is $3.12 per share on revenue of $5.8 billion. DexCom beat the EPS estimate in 10 of the last 12 quarters.
Related: DXCM income statement, DXCM key metrics, DXCM chart. See the DXCM stock overview for the latest quote and news.
DXCM forecast FAQ
What is DexCom's price target?
The average analyst price target for DexCom is $96.46, 12.1% above the latest close of $86.04.
Is DexCom a buy, hold or sell?
Of 29 analysts covering DexCom, 22 rate it a strong buy, 4 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is DexCom's EPS forecast?
Analysts forecast $2.66 per share for 2026 (range $2.45 to $2.75); for 2027 the estimate is $3.12.
What is DexCom's revenue forecast?
The average revenue estimate for 2026 is $5.2 billion, growth of 12.2%; for 2027 it is $5.8 billion.
When does DexCom report earnings?
DexCom is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 after the market closes; the EPS estimate is $0.66.
Does DexCom usually beat earnings estimates?
DexCom reported EPS at or above the analyst estimate in 10 of the last 12 quarters.